Dr. John Powderly, M.D.
Claim this profileCarolina BioOncology Institute
Expert in Solid Tumors
Expert in Tumors
39 reported clinical trials
68 drugs studied
About John Powderly, M.D.
Education:
- Received MD (Doctor of Medicine) from the University of Tennessee in 2006.
Experience:
- Founder and President of Carolina BioOncology Institute, also serving as an Oncologist.
- Focuses on Phase I immunotherapy clinical trials and cancer research.
- Manages on-site clinical laboratory services, including hematology and immunology.
- Specializes in translational tumor immunology research.
Area of expertise
1Solid Tumors
Global LeaderStage IV
Stage III
PD-L1 positive
2Tumors
Global LeaderStage IV
Stage III
EGFR positive
Affiliated Hospitals
Clinical Trials John Powderly, M.D. is currently running
TAB004 + Toripalimab
for Solid Cancers
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.
Recruiting1 award Phase 110 criteria
SIM1811-03
for Cutaneous T-Cell Lymphoma
This is a first in human, open-label, dose escalation and expansion Phase 1 study of SIM1811-03 in adult patients with advanced solid tumors and cutaneous T-cell lymphoma. SIM1811-03 is a first-in-class IgG1-based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors.
Recruiting1 award Phase 1
More about John Powderly, M.D.
Clinical Trial Related2 years of experience running clinical trials · Led 39 trials as a Principal Investigator · 20 Active Clinical TrialsTreatments John Powderly, M.D. has experience with
- Pembrolizumab
- Nivolumab
- Docetaxel
- Toripalimab
- Cetuximab
- MBRC-101
Breakdown of trials John Powderly, M.D. has run
Solid Tumors
Tumors
Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John Powderly, M.D. specialize in?
John Powderly, M.D. focuses on Solid Tumors and Tumors. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are Stage III.
Is John Powderly, M.D. currently recruiting for clinical trials?
Yes, John Powderly, M.D. is currently recruiting for 20 clinical trials in Huntersville North Carolina. If you're interested in participating, you should apply.
Are there any treatments that John Powderly, M.D. has studied deeply?
Yes, John Powderly, M.D. has studied treatments such as Pembrolizumab, Nivolumab, Docetaxel.
What is the best way to schedule an appointment with John Powderly, M.D.?
Apply for one of the trials that John Powderly, M.D. is conducting.
What is the office address of John Powderly, M.D.?
The office of John Powderly, M.D. is located at: Carolina BioOncology Institute, Huntersville, North Carolina 28078 United States. This is the address for their practice at the Carolina BioOncology Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.